SURGICAL INTERVENTIONS IN FACTOR VII DEFICIENCY: A SINGLE CENTER EXPERIENCE

FVII deficiency is the most common of the rare congenital bleeding disorders with a prevalence of about 1:500,000. Bleeding symptoms are considerably variable in terms of both location and severity, and may have a heterogenous spectrum ranging from asymptomatic conditions to serious/life-threatening...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Hematology, Transfusion and Cell Therapy Transfusion and Cell Therapy, 2024-05, Vol.46, p.4-4
Hauptverfasser: TÜZÜN, Betül Kübra, DEMİRCİ, Zühal, SEVGİLİ, Bahar, SAYDAM, Güray, ŞAHİN, Fahri
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:FVII deficiency is the most common of the rare congenital bleeding disorders with a prevalence of about 1:500,000. Bleeding symptoms are considerably variable in terms of both location and severity, and may have a heterogenous spectrum ranging from asymptomatic conditions to serious/life-threatening bleeds In surgical interventions, the duration of treatment and factor dose should be determined by considering the patient's previous and current bleeding clinic, factor level and comorbidities. We aimed to share our experience of surgical interventions and bleeding management in individuals with factor VII deficiency between January 2023 and January 2024 who followed up in our outpatient clinic. A total of 14 surgical interventions were performed in 12 patients with factor VII deficiency between January 2023 and January 2024 at Ege University Hemophilia Outpatient Clinic. 4 tooth extractions, 2 septorhinoplasties, 1 tympanoplasty, 1 tympanomastoidectomy, 1 lung wedge resection, 1 cataract and 4 orthopedic procedures (arthrodesis, radius fracture repair, total hip replacement and arthroscopy) were performed. The median age was 43 years (20-78 years), 7 of patients were female and 5 were male. 7 patients had ISTH bleeding score below 5 and 4 patients had no bleeding diathesis. Preoperative factor VII levels of the patients varied between 5-36%. Recombinant factor VIIa (rfVIIa) was used in 85% (n=12) and FFP in 15% (n=2) of the procedures. Median duration of treatment was 2.5 days (1-8 days). The median preoperative rfVIIa dose was 15 mcg/kg (10-30 mcg/kg), while the median single dose given in the postoperative period was 16.7 mcg/kg. While a single dose was administered in minor interventions such as tooth extraction, the mean number of total doses administered during treatment in other interventions was 11. In one patient, the procedure was performed with TDP due to the presence of both factor VII deficiency (FVII:36) and hypofibrinogenemia, low bleeding score and no previous history of postoperative bleeding. In another patient who underwent tooth extraction, the procedure was performed with FFP because the factor level was >30% and there was no previous bleeding history. The preoperative FFP dose was 15-20 ml/kg in patients that receiving FFP. Effective bleeding control was achieved and no thrombosis was observed in patients receiving both FFP and rFVIIa. The correlation between FVII activity and bleeding tendency is poor, although severe bleeding is most c
ISSN:2531-1379
DOI:10.1016/j.htct.2024.04.007